Video

PD-L1: An Important, But Imperfect Biomarker

Author(s):

H. Jack West, M.D.

Some immunotherapy drugs target the PD-L1 protein, though this expert says that it is still an imperfect biomarker.

In the lung cancer space, PD-L1 is not a perfect biomarker, says H. Jack West, M.D., thoracic oncologist, Swedish Cancer Institute at Swedish Medical Center.

PD-L1, a protein that immunotherapy drugs such as Keytruda (pembrolizumab) and Imfinzi (durvalumab) target, may not be as powerful a biomarker as ALK and EGFR. While PD-L1 status is often used to determine which patients should receive certain immunotherapy drugs, clinicians like West have also seen good promising response rates for patients given these agents who test low or negative for PD-L1.

Related Videos
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of woman with blonde hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Related Content
Illustration of lung.
March 6th 2025

Presurgical Opdivo Plus Yervoy Has Potential Clinical Benefit in NSCLC

Alex Biese
Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical benefits versus chemotherapy.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Illustration of lungs.
March 2nd 2025

First Patient With Small Cell Lung Cancer Dosed With Peluntamig

Spencer Feldman
The first patient with small cell lung cancer has been dosed in a trial of peluntamig (PT217) combined with chemotherapy.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Illustration of woman with black hair.
February 27th 2025

My Cousin and I Journey Through Breast, Lung, Pancreatic and Prostate Cancer

Sue McCarthy
After realizing that a stronger support system would have helped me emotionally and spiritually in my cancer journey, I committed myself to being there for my cousin.
Illustration of lungs.
February 27th 2025

Datroway May Be Effective in Non-Small Cell Lung Cancer Subtypes

Spencer Feldman
Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic alterations, including EGFR and ALK subgroups.